Literature DB >> 27683211

Characterization and genome sequencing of a Citrobacter freundii phage CfP1 harboring a lysin active against multidrug-resistant isolates.

Hugo Oliveira1, Graça Pinto1, Ana Oliveira1, Carla Oliveira1, Maria Alberta Faustino2, Yves Briers3,4, Lucília Domingues1, Joana Azeredo5.   

Abstract

Citrobacter spp., although frequently ignored, is emerging as an important nosocomial bacterium able to cause various superficial and systemic life-threatening infections. Considered to be hard-to-treat bacterium due to its pattern of high antibiotic resistance, it is important to develop effective measures for early and efficient therapy. In this study, the first myovirus (vB_CfrM_CfP1) lytic for Citrobacter freundii was microbiologically and genomically characterized. Its morphology, activity spectrum, burst size, and biophysical stability spectrum were determined. CfP1 specifically infects C. freundii, has broad host range (>85 %; 21 strains tested), a burst size of 45 PFU/cell, and is very stable under different temperatures (-20 to 50 °C) and pH (3 to 11) values. CfP1 demonstrated to be highly virulent against multidrug-resistant clinical isolates up to 12 antibiotics, including penicillins, cephalosporins, carbapenems, and fluroquinoles. Genomically, CfP1 has a dsDNA molecule with 180,219 bp with average GC content of 43.1 % and codes for 273 CDSs. The genome architecture is organized into function-specific gene clusters typical for tailed phages, sharing 46 to 94 % nucleotide identity to other Citrobacter phages. The lysin gene encoding a predicted D-Ala-D-Ala carboxypeptidase was also cloned and expressed in Escherichia coli and its activity evaluated in terms of pH, ionic strength, and temperature. The lysine optimum activity was reached at 20 mM HEPES, pH 7 at 37 °C, and was able to significantly reduce all C. freundii (>2 logs) as well as Citrobacter koseri (>4 logs) strains tested. Interestingly, the antimicrobial activity of this enzyme was performed without the need of pretreatment with outer membrane-destabilizing agents. These results indicate that CfP1 lysin is a good candidate to control problematic Citrobacter infections, for which current antibiotics are no longer effective.

Entities:  

Keywords:  Antibiotic resistances; Bacteriophages; Gram-negative bacteria; Phage lysins; Therapy

Mesh:

Substances:

Year:  2016        PMID: 27683211     DOI: 10.1007/s00253-016-7858-0

Source DB:  PubMed          Journal:  Appl Microbiol Biotechnol        ISSN: 0175-7598            Impact factor:   4.813


  20 in total

1.  A Tailspike with Exopolysaccharide Depolymerase Activity from a New Providencia stuartii Phage Makes Multidrug-Resistant Bacteria Susceptible to Serum-Mediated Killing.

Authors:  Hugo Oliveira; Graça Pinto; Bruna Mendes; Oscar Dias; Hanne Hendrix; Ergun Akturk; Jean-Paul Noben; Jan Gawor; Małgorzata Łobocka; Rob Lavigne; Joana Azeredo
Journal:  Appl Environ Microbiol       Date:  2020-06-17       Impact factor: 4.792

2.  Functional Analysis and Antivirulence Properties of a New Depolymerase from a Myovirus That Infects Acinetobacter baumannii Capsule K45.

Authors:  Hugo Oliveira; Ana Rita Costa; Alice Ferreira; Nico Konstantinides; Sílvio B Santos; Maarten Boon; Jean-Paul Noben; Rob Lavigne; Joana Azeredo
Journal:  J Virol       Date:  2019-02-05       Impact factor: 5.103

3.  A Lytic Providencia rettgeri Virus of Potential Therapeutic Value Is a Deep-Branching Member of the T5virus Genus.

Authors:  Hugo Oliveira; Graça Pinto; Hanne Hendrix; Jean-Paul Noben; Jan Gawor; Andrew M Kropinski; Małgorzata Łobocka; Rob Lavigne; Joana Azeredo
Journal:  Appl Environ Microbiol       Date:  2017-11-16       Impact factor: 4.792

Review 4.  Nanobiosystems for Antimicrobial Drug-Resistant Infections.

Authors:  Foteini Gkartziou; Nikolaos Giormezis; Iris Spiliopoulou; Sophia G Antimisiaris
Journal:  Nanomaterials (Basel)       Date:  2021-04-22       Impact factor: 5.076

5.  Characterization and genomic analyses of two newly isolated Morganella phages define distant members among Tevenvirinae and Autographivirinae subfamilies.

Authors:  Hugo Oliveira; Graça Pinto; Ana Oliveira; Jean-Paul Noben; Hanne Hendrix; Rob Lavigne; Małgorzata Łobocka; Andrew M Kropinski; Joana Azeredo
Journal:  Sci Rep       Date:  2017-04-07       Impact factor: 4.379

Review 6.  Phage-Derived Peptidoglycan Degrading Enzymes: Challenges and Future Prospects for In Vivo Therapy.

Authors:  Hugo Oliveira; Carlos São-José; Joana Azeredo
Journal:  Viruses       Date:  2018-05-29       Impact factor: 5.048

7.  Efficacy and safety assessment of two enterococci phages in an in vitro biofilm wound model.

Authors:  Luís D R Melo; R Ferreira; Ana R Costa; H Oliveira; J Azeredo
Journal:  Sci Rep       Date:  2019-04-30       Impact factor: 4.379

Review 8.  Treatment for carbapenem-resistant Enterobacterales infections: recent advances and future directions.

Authors:  Kathleen Tompkins; David van Duin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-06-24       Impact factor: 5.103

9.  Modular endolysin of Burkholderia AP3 phage has the largest lysozyme-like catalytic subunit discovered to date and no catalytic aspartate residue.

Authors:  Barbara Maciejewska; Karol Źrubek; Akbar Espaillat; Magdalena Wiśniewska; Krzysztof P Rembacz; Felipe Cava; Grzegorz Dubin; Zuzanna Drulis-Kawa
Journal:  Sci Rep       Date:  2017-11-06       Impact factor: 4.379

Review 10.  Phage Lysins for Fighting Bacterial Respiratory Infections: A New Generation of Antimicrobials.

Authors:  Roberto Vázquez; Ernesto García; Pedro García
Journal:  Front Immunol       Date:  2018-10-16       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.